Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LGVN
LGVN logo

LGVN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Longeveron Inc (LGVN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.070
1 Day change
-4.46%
52 Week Range
1.830
Analysis Updated At
2026/04/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Longeveron Inc (LGVN) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks immediate positive catalysts, and the financial performance shows declining revenue and negative net income. While technical indicators are mixed, there is no strong signal from proprietary trading tools or recent news to justify an immediate purchase.

Technical Analysis

The MACD histogram is positive but contracting, indicating weakening bullish momentum. RSI is neutral at 63.245, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 0.998, R1: 1.109, S1: 0.888, R2: 1.178, S2: 0.819. The stock has a 60% chance of minor price fluctuations in the short term (-0.49% in the next day, 1.28% in the next week, -2.87% in the next month).

Positive Catalysts

  • The company has a high gross margin of 91.24%, which increased by 3.81% YoY. Analysts maintain a Buy rating, expecting positive data from the ELPIS II study in Q3 2026, with a potential BLA filing in 2027.

Neutral/Negative Catalysts

  • Net income remains negative at -$5.44M, despite a YoY improvement. EPS is still negative at -0.

  • There is no recent news or significant trading activity from hedge funds, insiders, or Congress. Analysts have lowered the price target from $3 to $2.

Financial Performance

In Q4 2025, revenue dropped to $365,000 (-39.47% YoY). Net income improved YoY but remains negative at -$5.44M. EPS increased to -0.39 (+44.44% YoY). Gross margin improved to 91.24% (+3.81% YoY). Overall, the financials show a struggling company with declining revenue but slight improvements in profitability metrics.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Roth Capital lowered the price target from $3 to $2 but maintained a Buy rating. Analysts expect positive data from the ELPIS II study in Q3 2026, with a potential BLA filing in 2027.

Wall Street analysts forecast LGVN stock price to rise
2 Analyst Rating
Wall Street analysts forecast LGVN stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.120
sliders
Low
3
Averages
3.5
High
4
Current: 1.120
sliders
Low
3
Averages
3.5
High
4
Roth Capital
Buy
downgrade
$3 -> $2
AI Analysis
2026-03-18
Reason
Roth Capital
Price Target
$3 -> $2
AI Analysis
2026-03-18
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Longeveron to $2 from $3 but keeps a Buy rating on the shares. The firm continues to expect top-line data from the ELPIS II study evaluating Laromestrocel in HLHS - hypoplastic left heart syndrome - patients in Q3 of this year, and if positive, a BLA filing is expected to occur in 2027, the analyst tells investors in a research note.
Roth Capital
Buy
downgrade
$10 -> $3
2025-08-15
Reason
Roth Capital
Price Target
$10 -> $3
2025-08-15
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Longeveron to $3 from $10 and keeps a Buy rating on the shares. The firm's price target cut reflects Q2 results and the dilutive equity financing earlier this week, though Longeveron remains an underappreciated firm despite its first-mover advantage in HLHS, or Hypoplastic Left Heart Syndrome, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LGVN
Unlock Now

People Also Watch